Genomes2Veterans

Jason Vassy, MD, MPH, SM

As director of the Genomes2Veterans research program at the Veterans Affairs (VA) Boston Healthcare System, Jason Vassy, MD, MPH, SM, bridges the expertise of Genomes2People and the mission of bringing 21st century medical care to Veterans.

Genomes2Veterans research team:

Sanjay Advani, MA

Research Coordinator
Genomes2Veterans
617-352-6900

Charles Brunette, PhD

Project Manager
Genomes2Veterans
857-364-6324

Jason Vassy, MD, MPH, SM

Assistant Professor, Medicine
Director, Genomes2Veterans
857-364-2561

Current Genomes2Veterans research projects:

Integrating Pharmacogenetics in Clinical Care (I-PICC) Study
Funding: U.S. Department of Veterans Affairs Office of Research & Development IK2-CX001262
Project Manager: Charles Brunette, PhD

The I-PICC Study is a pragmatic randomized controlled trial of pharmacogenetic testing for statin myopathy risk in the eight primary care practices across VA Boston. Statin-naïve patients at higher risk for cardiovascular disease are randomly assigned at the point-of-care to have their primary care providers receive their SLCO1B1 genotype results at baseline or at the end of the study. Patients are followed in the electronic health record for 12 months for outcomes including cholesterol levels, statin-associated muscle symptoms, and concordance with cardiovascular disease and pharmacogenetic prescribing guidelines.

For more detailed information about the I-PICC Project, including study design and outcome measures, visit our clinical trial page:

I-PICC on ClinicalTrials.gov

 

PRecision medicine In MEntal Health (PRIME) Care Study
Funding: U.S. Department of Veterans Affairs Office of Research & Development SDR 16-348
Research Coordinator: Sanjay Advani, MA

VA Boston is one of 19 VA sites across the county participating the PRIME Care Study, a randomized controlled trial of pharmacogenetic testing to guide antidepressant prescribing among patients with major depressive disorder. The PRIME Care Study is testing the hypothesis that pharmacogenetics-guided prescribing will improve rates of depression remission compared to current standard of care.

For more detailed information about the PRIME Care Study, including study design and outcome measures, visit our clinical trial page:

PRIME Care on ClinicalTrials.gov

 

For Genomes2Veterans scientific papers and media coverage, visit the link below.

G2V Publications

G2V News & Media

Latest News From Genomes2People